Dr. Niclas Stiernholm | President and Chief Executive Officer
Dr. Stiernholm's primary responsibilities at SCT include overseeing the company's strategic direction, executing business development plans and ensuring that the company's scientific programs continue to advance in good time. Dr. Stiernholm was previously the Chief Executive Officer of Trillium Therapeutics. He joined Trillium from YM BioSciences where he acted as Executive Vice President and Chief Scientific Officer. While there, he played a significant role in the success of their Initial Public Offering (IPO) in 2002. Dr. Stiernholm began his industry career as a member of Allelix Biopharmaceuticals' business development office. He currently serves on the boards of the Ontario Genomics Institute, AvidBiologics and Stem Cell Therapeutics. He received his Ph.D. in immunology from the University of Toronto, where he also completed his postdoctoral training.
Dr. Bob Uger | Chief Scientific Officer
Dr. Uger is responsible for developing and implementing the scientific direction of SCT, and oversees both internal product development and external research discovery programs. He also acts as the company’s scientific liaison with respect to global collaborations with academic and hospital research scientists. Dr. Uger was previously Vice-President, Research & Development at Trillium Therapeutics. He joined Trillium from Aventis Pasteur where he was a Senior Research Scientist involved in cancer vaccine research. He received his Ph.D. in immunology from the University of Toronto.
Dr. Penka Petrova | Vice President, Drug Development
Dr. Petrova is responsible for managing the company's formal drug development efforts, including all outsourced activities to CMOs and CROs. In addition, she continues to serve as the Head of SCT’s cell biology group and oversees all the company's in vivo studies. Dr. Petrova was previously Director, Drug Development at Trillium Therapeutics. She joined Trillium from Prescient Neuropharma in 2003, where she held a Research Scientist position and was involved in identifying and characterizing novel proteins involved in neuroprotection. Dr. Petrova received her Ph.D. in Microbiology from Saarland University in Saarbruecken, Germany, where she also conducted her post doctoral studies.
Mr. James Parsons | Chief Financial Officer
Mr. Parsons has had a long and successful career in the biotechnology industry, has extensive experience with financing, product licensing, corporate governance and operational management in this arena and he has been intimately involved in the conversion by numerous biotechnology companies to the new reporting standards known as IFRS. Mr. Parsons’ involvement in biotechnology has spanned both private and public companies including Amorfix Life Sciences Ltd, DiaMedica Inc, Rimon Therapeutics Ltd, Trillium Therapeutics Inc and YM BioSciences Inc.
Mr. Scott Duncan | Director of Intellectual Property
Mr. Duncan is recognized for the quality of his patent consulting services which he has provided for the past 12 years to a diverse range of biotechnology companies since he built and managed Canada’s largest biotech patent estate during his tenure with Allelix, one of Canada's initial biotech companies that was acquired by NPS Pharmaceuticals of Salt Lake City. His responsibilities within that role included the development of patent assets relating to transgenic crops, medicinal chemistry, protein drugs and expression systems, and in vitro diagnostics. Mr. Duncan has been a registered patent agent since 1986, when he qualified magna cum laude while working at a Toronto firm specializing in intellectual property.